Document:

Exhibit 10.27

 

August
24, 2007

 

Monosol Rx, LLC

30 Technology Drive

Warren, NJ 07059

 

Gentlemen:

 

You have advised us that Monosol Rx, LLC, a Delaware
limited liability company (the “Borrower”), seeks financing for ongoing working
capital requirements and other general purposes, as more fully described in the
attached Summary of Terms and Conditions (the “Term Sheet”).  The Term Sheet describes the general terms
and conditions for a $10,000,000 senior secured revolving credit facility (the “Facility”).

 

Based on and subject to the terms and conditions set
forth in this commitment letter (the “Commitment Letter”) and in the Term
Sheet, we hereby advise you of our commitment to provide (or to cause one or
more of our respective affiliates to provide) the Facility, in the amounts set
forth beside the signatures of the undersigned below.

 

The term of this Commitment Letter shall, except as
otherwise set forth herein, commence on the date of this Commitment Letter and
shall expire on the earlier of (i) 360 days after the date of this letter, and
(ii) the date of execution and delivery of the definitive financing
documentation for the Facility (the “Closing Date”).

 

The commitments made under this Commitment Letter are
based on the financial and other information regarding the Borrower previously
provided to us.  Accordingly, those commitments
are subject to the satisfaction of each of the following conditions:

 

(i)                                     Each
of the terms and conditions set forth in this Commitment Letter and in the Term
Sheet;

 

(ii)                                  The
absence of a material breach of any representation, warranty or agreement of
the Borrower set forth in this Commitment Letter;

 

(iii)                               No
change, occurrence or development that would reasonably be expected to have a
material adverse effect on the business, assets, liabilities, operations,
condition (financial or otherwise) or prospects of the Borrower shall have
occurred or become known to us;

 

(iv)                              The
information concerning the Borrower shall not differ in any material adverse
manner from the information and other matters previously disclosed to us before
the date of this Commitment Letter;

 

(v)                                 Material
compliance with all applicable laws and regulations by the Borrower;

 

 

(vi)                              The
negotiation, execution and delivery of definitive documentation for the Facility
consistent with the Term Sheet; and

 

(vii)                           The
board of directors of Monosol Rx, Inc. shall have made no decision to
discontinue the pursuit of its currently proposed initial public offering.

 

No delay in the commencement or completion of that
initial public offering shall be deemed a failure to satisfy any of the
aforementioned conditions set forth in this Commitment Letter or in the Term
Sheet.

 

You represent, warrant and covenant that: (i) all
information other than Projections (as defined below), that has been or is,
after the date of this Commitment Letter, made available to the undersigned by
you or any of your representatives in connection with the transactions
described in this Commitment Letter (the “Information”) is and will be complete
and correct in all material respects as of the date made available to us and
does not and will not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements contained therein not
materially misleading; and (ii) all financial projections concerning the
Borrower that have been or, after the date of this Commitment Letter, are made
available to us by you or any of your representatives (the “Projections”) have
been or will be prepared in good faith based on assumptions you believe to be
reasonable.  You agree to furnish us such
Information and Projections as we may reasonably request and to supplement the
Information and the Projections from time to time until the Closing Date so
that the representation, warranty and covenant in the preceding sentence is
correct on the Closing Date.

 

This Commitment Letter is addressed solely to you, as
the Borrower, and is not intended to confer any obligations to or on, or
benefits to or on any other person.

 

You may disclose the terms of this Commitment Letter
and the Term Sheet (i) to your attorneys, financial advisors and accountants,
(ii) to any underwriters or proposed underwriters in connection with your
proposed initial public offering and (iii) in any filing with the Securities
and Exchange Commission (including any amendment to your Registration Statement
on Form S-1) or with the National Association of Securities Dealers in
connection with your proposed initial public offering.  You acknowledge and agree that we may share
with our affiliates any information relating to the Facility, this Commitment
Letter and the Term Sheet.  The
provisions of this paragraph shall remain in full force and effect regardless
of whether definitive financial documentation shall be executed and delivered
and notwithstanding the termination of this Commitment Letter.

 

Our commitment with respect to the Facility under this
Commitment Letter shall terminate at 5:00 p.m. eastern daylight time on August 31,
2007 (the “Acceptance Deadline”), unless this Commitment Letter is accepted by
you in writing and delivered to us before such time.

 

2

 

This Commitment Letter, together with the Term Sheet,
embodies the entire agreement and understanding between you and us with respect
to the specific matters set forth in this Commitment Letter and the Term Sheet
and supersedes all prior agreements and understandings related to the subject
matter of this Commitment Letter and the Term Sheet.

 

This Commitment Letter shall be governed by and
construed in accordance with the laws of the State of New York without regard
to the conflicts of law provisions of the State of New York.  You and we irrevocably waive all right to
trial by jury in any action, proceeding or counterclaim arising out of or
relating to this Commitment Letter or the Term Sheet.

 

This Commitment Letter may be executed in any number
of counterparts, each of which shall be an original, and all of which, when
taken together, shall constitute one agreement. 
Delivery of an executed signature page of this Commitment Letter by
facsimile transmission shall be effective as delivery of a manually executed
counterpart of this Commitment Letter, provided that the facsimile transmission
shall be promptly followed by the original thereof.

 

Neither this Commitment Letter nor the Term Sheet may
be amended, and no provision of this Commitment Letter or the Term Sheet waived
or modified, except by an instrument in writing signed by the undersigned and
you.

 

This Commitment Letter may not be assigned by you
without the prior written consent of the undersigned, and any purported
assignment without such consent shall be null and void.

 

Please indicate your acceptance of this Commitment
Letter and the Term Sheet by signing in the space provided and returning an
original copy bearing your signature to us on or before the Acceptance
Deadline.  We are pleased to have the
opportunity to assist you in connection with this proposed financing
transaction.

 

	
   

  	
  Very truly
  yours,

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  MONOLINE RX,
  L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  BRATTON CAPITAL,
  INC.,

  
	
   

  	
   

  	
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ John Cochran

  	
   

  
	
   

  	
   

  	
  Name:

  	
  John Cochran

  	
   

  
	
   

  	
   

  	
  Title:

  	
  V.P.

  	
   

  
	
   

  	
   

  	
   

  
						

 

	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  MONOLINE RX II,
  L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  BRATTON CAPITAL,
  INC.,

  
	
   

  	
   

  	
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ John Cochran

  	
   

  
	
   

  	
   

  	
  Name:

  	
  John Cochran

  	
   

  
	
   

  	
   

  	
  Title:

  	
  V.P.

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Aggregate
  amount of commitment of MonoLine RX, 

  
	
   

  	
  L.P.,
  MonoLine RX II, L.P. and affiliated entities:

  
	
   

  	
           $8,327,000

  
						

 

3

 

	
   

  	
  HALIFAX MONOSOL
  INVESTORS, L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  HALIFAX GENPAR
  MONOSOL, LLC,

  
	
   

  	
   

  	
  its General
  Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ A. Judson
  Hill

  	
   

  
	
   

  	
   

  	
  Name:

  	
  A. Judson Hill

  	
   

  
	
   

  	
   

  	
  Title:

  	
  Managing
  Director

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Amount
  of commitment:             $1,673,000

  

 

 

	
  ACCEPTED AND AGREED TO
  ON

  	
   

  	 

	
  AUGUST 24, 2007:

  	
   

  	 

	
   

  	
   

  	 

	
  MONOSOL RX, LLC

  	 

	
   

  	
   

  	 

	
  By:

  	
  MONOSOL RX GENPAR,
  L.P., its Manager

  	 

	
   

  	
   

  	 

	
  By:

  	
  BRATTON CAPITAL, INC.,
  its General Partner

  	 

	
   

  	
   

  	 

	
   

  	
  By:

  	
  /s/ John Cochran

  	
   

  
	
   

  	
   

  	
  Name:

  	
  John Cochran

  	
   

  	
   

  
	
   

  	
   

  	
  Title:

  	
  V.P.

  	
   

  
								

 

 

4

 

Attachment to Commitment
Letter

 

MONOSOL RX, LLC

SUMMARY OF TERMS AND CONDITIONS

$10,000,000 SENIOR SECURED CREDIT FACILITY

August 24, 2007

 

 

	
  BORROWER:

  	
   

  	
  Monosol Rx, LLC, a
  Delaware limited liability company (the “Borrower”)

  
	
   

  	
   

  	
   

  
	
  LENDERS:

  	
   

  	
  MonoLine RX, L.P.,
  MonoLine RX II, L.P. and Halifax Monosol Investors, L.P., or their respective
  appointed affiliates (collectively, the “Lenders”)

  
	
   

  	
   

  	
   

  
	
  FACILITY:

  	
   

  	
  A $10,000,000 revolving
  credit facility (the “Facility”). 
  Subject to the limitations described in this term sheet, revolving
  credit loans may be repaid and reborrowed.

  
	
   

  	
   

  	
   

  
	
  AVAILABILITY OF LOANS:

  	
   

  	
  Loans under the
  Facility shall be available until the earlier of (i) the Maturity Date (as
  defined below) and (ii) the date that the board of directors of Monosol Rx,
  Inc. determines that Monosol Rx, Inc. will not further pursue its currently
  proposed initial public offering.

  
	
   

  	
   

  	
   

  
	
  MATURITY DATE:

  	
   

  	
  All amounts outstanding
  under the Facility shall be due and payable in full on the earliest of (i)
  the fifth business day after the completion of Monosol Rx, Inc.’s currently
  proposed initial public offering; (ii) the fifth business day after the
  completion of any private equity financing of the Borrower in lieu of Monosol
  Rx, Inc.’s currently proposed initial public offering, and (iii) 360 days
  after the date of the Borrower’s acceptance of the Commitment Letter to which
  this term sheet is attached (the “Maturity Date”).

  
	
   

  	
   

  	
   

  
	
  PURPOSE:

  	
   

  	
  The Facility shall be
  used (i) for the Borrower’s general company purposes, including, without
  limitation, working capital and capital expenditures in the ordinary course
  of business, and (ii) to pay the Borrower’s fees and expenses related to the
  Facility.

  
	
   

  	
   

  	
   

  
	
  SECURITY:

  	
   

  	
  The Lenders shall
  receive first priority perfected security interest in all assets, tangible
  and intangible, of the Borrower (the “Collateral”).  All such security interests shall be
  created on terms, and pursuant to customary documentation satisfactory to the
  Lenders and none of the Collateral shall be subject to any other security
  interests except as permitted in writing by the Lenders.

  

 

 

	
  INTEREST RATE:

  	
   

  	
  For each loan, the
  LIBOR Rate plus 400 basis points.  The
  LIBOR Rate shall mean the rate per annum appearing on Reuters Screen LIBOR 01
  Page (or any successor or substitute page of such service, or any successor
  for such service), at approximately 11:00 a.m. London time two business days
  before making the applicable loan, offered for U.S. dollar deposits with a
  maturity comparable to that of the applicable loan.  LIBOR Rate and all fees shall be calculated
  on a 360-day basis.

  
	
   

  	
   

  	
   

  
	
  INTEREST

  PAYMENTS:

  	
   

  	
  Interest on loans will
  be due and payable on the Maturity Date.

  
	
   

  	
   

  	
   

  
	
  COMMITMENT

  FEE:

  	
   

  	
  The Borrower shall pay
  a total commitment fee of 75 basis points with 50% payable at the time of the
  Borrower’s acceptance of the Commitment Letter, and the remaining 50% payable
  on the Maturity Date.  The commitment
  fee shall be allocated between the Lenders in accordance with the amounts of
  their commitments.

  
	
   

  	
   

  	
   

  
	
  LOANS UNDER

  THE

  CREDIT

  FACILITY:

  	
   

  	
  Borrowings may be
  requested upon ten (10) business days’ notice.  Notice must be given to each Lender by 1:00
  p.m. Eastern time, on the day on which the notice is required.

  
	
   

  	
   

  	
   

  
	
  REPAYMENT:

  	
   

  	
  The Facility shall be
  repaid in full, including any unpaid interest, on the Maturity Date.

  
	
   

  	
   

  	
   

  
	
  OPTIONAL

  PREPAYMENTS:

  	
   

  	
  Loans may be
  prepaid before the Maturity Date at any time without penalty.  Any such prepayment shall not reduce the
  amount of the Facility.

  
	
   

  	
   

  	
   

  
	
  CONDITIONS

  PRECEDENT TO

  CLOSING:

  	
   

  	
  1.The negotiation, execution and delivery of
  definitive credit documentation for the Facility in form and substance
  satisfactory to the Lenders.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  2.All governmental and other third-party consents
  and approvals necessary in connection with the Facility shall have been
  obtained and remain in effect.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  3.No change, occurrence or development that would
  reasonably be expected to have a material adverse effect on the business,
  assets, liabilities, operations, condition (financial or otherwise) or
  prospects of the Borrower shall have occurred or become known to the Lenders.

  

 

6

 

	
   

  	
   

  	
  4.There
  shall be no pending or threatened litigation, bankruptcy or insolvency,
  injunction, order or claim with respect to the Borrower that could reasonably
  be expected to have a material adverse effect on the financial condition of
  the Borrower, or on the ability of the Borrower to perform its obligations
  under the Facility.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  5.The Lenders shall
  have received payment of the commitment fees that are due and payable at or
  before the closing date of the Facility.

  
	
   

  	
   

  	
   

  
	
  CONDITIONS

  PRECEDENT TO

  ALL

  BORROWINGS:

  	
   

  	
  Customary for
  facilities of this nature, including, but not limited to, company existence;
  company and governmental authorization; financial information; no material
  adverse changes; compliance with laws and agreements; title to assets;
  material contracts; no material litigation; payment of taxes; financial
  condition; and full disclosure.

  
	
   

  	
   

  	
   

  
	
  AFFIRMATIVE

  COVENANTS:

  	
   

  	
  Customary for
  facilities of this nature, including, but not limited to, receipt of
  financial information; notification of litigation (with a materiality
  threshold to be determined), investigations and other adverse changes;
  payment and performance of obligations; conduct of business; maintenance of
  existence; maintenance of property and insurance (including hazard and
  business interruption coverage); maintenance of records and accounts;
  inspection of property and books and records; compliance with laws; and
  payment of taxes.

  
	
   

  	
   

  	
   

  
	
  NEGATIVE

  COVENANTS:

  	
   

  	
  Customary for facilities
  of this nature, including, but not limited to, restrictions and limitations
  on: indebtedness (except for unsecured debt; liens; guaranty obligations;
  material changes in business; mergers (other than the proposed merger of the
  Borrower with and into Monosol Rx, Inc.); sales of assets outside of the
  ordinary course of business; acquisitions of businesses; loans and
  investments; transactions with affiliates; and prepayments of or material
  amendments to indebtedness (including, without limitation, repayment of any
  subordinated debt).

  
	
   

  	
   

  	
   

  
	
  EVENTS OF

  DEFAULT:

  	
   

  	
  Customary for
  facilities of this nature, including, but not limited to, failure to pay any
  interest, principal or fees under the Facility when due; failure to perform
  any covenant or agreement; representations or warranties being inaccurate or
  false when made; invalidity of any security interest in favor of the Lenders;
  insolvency or bankruptcy; judgment defaults; and change in control.

  
	
   

  	
   

  	
   

  
	
  ASSIGNMENTS

  AND

  PARTICIPATIONS:

  	
   

  	
  Lenders will not be
  permitted to make assignments or participations without the consent of the
  Borrower.

  

 

7

 

	
  WAIVERS AND

  AMENDMENTS:

  	
   

  	
  Amendments and waivers
  of the provisions of the definitive credit documentation will require the approval
  of the Required Lenders, except that the consent of all the Lenders affected
  thereby shall be required with respect to (i) increases in commitments, (ii)
  reductions of principal, interest or fees, (iii) extensions of scheduled
  maturities or times for payment, and (iv) releases of all or substantially
  all of the value of the Collateral. “Required Lenders” means, on any
  date of determination, those Lenders who collectively hold more than 50% of
  the Facility, or if the Facility has been terminated, those Lenders who
  collectively hold more than 50% of the aggregate outstandings.

  
	
   

  	
   

  	
   

  
	
  WAIVER OF JURY

  TRIAL,

  GOVERNING LAW:

  	
   

  	
  Waiver of jury trial,
  submission to jurisdiction in New York, New York and mandatory binding
  arbitration in New York, New York; New York law (without reference to choice
  of law provisions) to govern.

  
	
   

  	
   

  	
   

  
	
  MISCELLANEOUS:

  	
   

  	
  This summary of terms
  and conditions does not purport to summarize all the conditions, covenants,
  representations, warranties and other provisions that would be contained in
  definitive credit documentation for the Facility.

  

 

8Exhibit 4.6

 

	
  Rights Certificate No. :

  	
  NUMBER
  OF RIGHTS:

  

 

THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH
IN THE COMPANY’S PROSPECTUS SUPPLEMENT DATED        
TO THE PROSPECTUS DATED         (TOGETHER,
THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE
PROSPECTUS ARE AVAILABLE UPON REQUEST FROM         ,
THE INFORMATION AGENT.

 

KKR FINANCIAL HOLDINGS LLC

A limited
liability company formed under the laws of the State of Delaware

 

[NON - ] TRANSFERABLE
SUBSCRIPTION RIGHTS CERTIFICATE

 

Evidencing [Non -]
Transferable Subscription Rights to Purchase [Common] [Preferred] Shares of KKR
Financial Holdings LLC

Subscription Price: $      
per Share

 

THE
SUBSCRIPTION RIGHTS WILL EXPIRE IF NOT EXERCISED ON OR BEFORE         ,
NEW YORK CITY TIME, ON         , UNLESS
THE TIME IN WHICH TO EXERCISE THE RIGHT IS EXTENDED BY THE COMPANY

 

REGISTERED OWNER:

 

THIS CERTIFIES THAT the
registered owner whose name is inscribed hereon is the owner of the number of
[non-] transferable subscription rights (“Rights”) set forth above. Each whole
Right entitles the holder thereof to subscribe for and purchase one [Common]
[Preferred]  Share of KKR Financial
Holdings LLC, a Delaware limited liability company, at a subscription price of
$         per share (the
“Subscription Privilege”), pursuant to a rights offering (the “Rights
Offering”), on the terms and subject to the conditions set forth in the
Prospectus and the “Instructions as to Use of KKR Financial Holdings LLC
Subscription Rights Certificates” accompanying this Subscription Rights
Certificate. The Rights represented by this Subscription Rights Certificate may
be exercised by completing Form 1 and any other appropriate forms on the
reverse side hereof and by returning the full payment of the subscription price
for each [Common] [Preferred] Share in accordance with the “Instructions as to
Use of KKR Financial Holdings LLC Subscription Rights Certificates” that
accompany this Subscription Rights Certificate.

 

This Subscription Rights
Certificate is not valid unless countersigned by the subscription agent and
registered by the registrar.

 

Witness the signatures of the
duly authorized officers of KKR Financial Holdings LLC.

 

 

	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  [Name]

  	
   

  	
   

  	
   

  	
  [Name]

  	
   

  
	
   

  	
  [Title]

  	
   

  	
   

  	
   

  	
  [Title]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  COUNTERSIGNED AND REGISTERED:

  	
   

  
	
   

  
	
   

  
	
   

  
	
  By:

  	
   

  	
   

  	
   

  
	
                                                               AUTHORIZED
  SIGNATURE

  
				

 

 

DELIVERY
OPTIONS FOR SUBSCRIPTION RIGHTS CERTIFICATE

 

	
  For delivery by mail or over night courier:

  	
   

  	
  For hand delivery:

  
	
  [Subscription Agent]

  	
   

  	
  [Subscription Agent]

  
	
  [Address]

  	
   

  	
  [Address]

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  

 

Delivery other than in the manner or to the addresses listed above will
not constitute valid delivery.

 

PLEASE PRINT ALL INFORMATION CLEARLY AND LEGIBLY.

 

	
  FORM
  1-EXERCISE OF SUBSCRIPTION RIGHTS

  	
   

  	
  FORM 3-
  SIGNATURE

  
	
   

  	
   

  	
   

  
	
  To subscribe for shares
  pursuant to your Subscription Privilege, please complete line (a) and sign
  under Form 3 below.

  	
   

  	
  I acknowledge that I have
  received the Prospectus for this Rights Offering and I hereby
  irrevocably subscribe for the 

  
	
   

  	
   

  	
  number of shares
  indicated above on the terms and conditions specified in the Prospectus.

  
	
  (a) EXERCISE OF
  SUBSCRIPTION PRIVILEGE:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  I apply for

  	
   

  	
   shares x  $

  	
   

  	
  = $

  	
   

  	
   

  	
   

  
	
                (no.
  of new shares)            (subscription
  price)    (Payment)

  	
   

  	
  Signature(s)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  IMPORTANT: The signature(s)
  must correspond with the

  
	
  METHOD OF PAYMENT (CHECK
  ONE)

  	
   

  	
  name(s) as printed on the
  reverse of this Subscription Rights

  
	
   

  	
   

  	
  Certificate on every particular,
  without alteration or enlargement,

  
	
   

  	
   

  	
   

  	
  or any other change
  whatsoever

  
	
  o

  	
  Check or bank draft drawn
  on a U.S. bank, or postal, telegraphic or express money order payable to “[Subscription
  Agent], as Subscription Agent.” Funds paid by an uncertified check may take
  at least five business days to clear.

  	
   

  	
  

  

  

  FORM 4-SIGNATURE GUARANTEE

  
	
   

  	
   

  	
   

  	
  This form must be completed
  if you have completed Form 2.

  
	
  o

  	
  Wire transfer of
  immediately available funds directly to the account maintained by [Subscription
  Agent], as Subscription Agent, for purposes of accepting subscriptions in
  this Rights Offering at       

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Signature Guaranteed:

  	
   

  	
   

  
	
  FORM
  2-DELIVERY TO DIFFERENT ADDRESS

  	
   

  	
                                                    (Name
  of Bank or Firm)

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
  If you wish for the [Common]
  [Preferred] Shares underlying your subscription rights to be delivered
  to an address different from that shown on the face of this Subscription
  Rights Certificate, please enter the alternate address below, sign under Form
  3 and have your signature guaranteed under Form 4.

  	
   

  	
                                                   (Signature
  of Officer)

  
	
   

  	
  

  IMPORTANT: The signature(s) should be guaranteed by an eligible guarantor
  institution (bank, stock broker, savings & loan association or credit union)
  with membership in an approved signature guarantee medallion program pursuant
  to Securities and Exchange Commission Rule 17Ad-15.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
												

 

This Subscription Rights
Certificate and the Rights represented hereby shall be governed by, and
construed in accordence with, the law of the State of Delaware.

 

FOR INSTRUCTIONS ON THE USE OF
KKR FINANCIAL HOLDINGS LLC SUBSCRIPTION RIGHTS CERTIFICATES, CONSULT           ,
THE INFORMATION AGENT, AT            
AND BANKS AND BROKERS MAY CALL THE INFORMATION AGENT AT           .

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]